A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer.

Trial Profile

A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs Sorafenib (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PECASO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Dec 2012 Additional lead trial centre added as reported by German Clinical Trials Register.
    • 01 Aug 2012 New source identified and integrated (DRKS00003807: German Clinical Trials Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top